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Molecular ‘‘hitchhiking’’ through receptor-mediated transcytosis at the blood-brain barrier is a CNS drug
delivery strategy. In this issue of Neuron, Niewoehner et al. (2014) describe a modular anti-transferrin
receptor Fab approach for shuttling therapeutic antibodies into the brain.The blood-brain barrier (BBB) is lined
with brain endothelial cells, sealed with
paracellular protein complexes, bound
by extracellular matrix, and maintained
through pericyte and glial interactions
(Zlokovic, 2008). Through its ability to
restrict penetration of biomolecules, the
BBB regulates the chemical composition
of the CNS required for proper neuronal
function. While vital for health and normal
physiology, the BBB remains an obstacle
for delivery of therapeutics into the
brain. In particular, large biologics includ-
ing peptides and antibodies exhibit a
restricted ability to cross the BBB (Par-
dridge, 2012; Yu andWatts, 2013). There-
fore, the development of noninvasive
strategies to enhance macromolecule
delivery across the BBB has been a
long-sought objective for academic and
biopharmaceutical research. A variety of
approaches including nanoparticles,
liposomes, vesicles, peptide conjugates,
viruses, and antibodies are being pur-
sued, most with mixed results (Pardridge,
2012; Ramos-Cabrer and Campos, 2013;
Yu and Watts, 2013). Although consider-
able preclinical data exist using these
BBB transport strategies, none of these
approaches are known to be efficacious
in treating human CNS disorders.
The main barriers that regulate mole-
cular exchange between blood and brain
include choroid plexus and arachnoid
epithelium for exchange between blood
and CSF, and the BBB separating blood
from brain parenchyma. While epithelial
barriers permit passive transport, large
molecules in CSF are rapidly cleared into
blood via bulk flow and diffuse poorly
into the brain parenchyma (Pardridge,
2012). Therefore, due to the substantial
surface area for molecular transport, the
BBB is considered the primary interface
for drugs to effectively penetrate thebrain. While small lipid-soluble molecules
can enter the CNS through passive
transport, specialized carriers and recep-
tors actively mediate transport of small
water-soluble, polar molecules and mac-
romolecules across the BBB (Zlokovic,
2008). For example, carrier-mediated
transport pathways exist for glucose,
amino acids, and nucleosides (e.g.,
adenosine), whereas receptor-mediated
transcytosis (RMT) pathways carry mac-
romolecules such as insulin, leptin, and
transferrin into the brain. Transcytosis is
a process by which macromolecules are
transported within membrane bound
vesicles between apical and basolateral
domains of polarized cells (Tuma and
Hubbard, 2003). Among transcytotic
cargo of the cerebrovascular endothe-
lium, the transferrin receptor (TfR) has
been particularly well studied as a means
to target drug delivery into the CNS.
Whereas most studies have utilized a
TfR antibody carrying therapeutic cargo
(Pardridge, 2012) or a bivalent antibody
in which one arm binds TfR and the
other a disease target (Yu et al., 2011),
in this issue of Neuron, Niewoehner et al.
(2014) developed an anti-TfR Fab to
mediate BBB transcytosis of an attached
immunoglobulin. To test the therapeutic
potential of this ‘‘Brain Shuttle,’’ Niewoeh-
ner et al. (2014) re-engineered a mono-
clonal antibody (mAb) against Ab, the
toxic peptide that accumulates in Alz-
heimer’s disease (Bohrmann et al., 2012),
by fusing the anti-TfR Fab to the C termi-
nus of the anti-Ab mAb in a monovalent
fashion (Figure 1A). Notably, this Brain
Shuttle-modified anti-Ab showed signifi-
cantly enhanced brain penetration and
amyloid plaque reduction in a transgenic
mouse model of Alzheimer’s disease.
As early as 1984, Jefferies discovered
the abundance of TfR on brain capillariesNeuronthat functions to deliver iron-bound trans-
ferrin into the brain (Jefferies et al., 1984).
Nearly a decade later, experiments using
radiolabeled tracers demonstrated that
TfR antibodies can cross the BBB (Par-
dridge et al., 1991) and deliver therapeutic
payloads such as methotrexate (Friden
et al., 1991). Since then, significant effort
has been made to identify the molecular
mechanisms and therapeutic potential of
TfR or other RMT pathways for delivering
biologics into the brain. Transferrin or
transferrin mimetic peptides fused to
a therapeutic cargo are minimally effec-
tive in BBB transport due to high levels
of competing endogenous transferrin
in blood. However, antibodies against
TfR that do not disrupt transferrin bind-
ing have been developed and shown
to transport macromolecules including
glial-derived neurotrophic factor (GDNF),
erythropoietin (EPO), tumor necrosis
factor receptor II (TNFR-II), and various
enzymes across the BBB in preclinical
models (Pardridge, 2012). Recently,
a bispecific antibody with one arm that
binds TfR and another arm that binds
BACE1 was described (Yu et al., 2011).
BACE1 is a membrane-associated aspar-
tyl protease that mediates initial cleavage
of the amyloid precursor protein (APP)
required for generation of Ab. This bispe-
cific antibody significantly reduced cen-
tral Ab levels even after a single dose
(Yu et al., 2011), presumably by inhibiting
or targeting BACE1 for degradation.
Notably, Yu et al. found that lower affinity
anti-TfR antibodies showed increased
brain uptake, whereas antibodies with
high affinity to TfR remained inside the
neurovasculature. The efforts described
above established a foundation for
developing RMT therapeutic delivery
strategies for treatment of CNS disorders,
such as the approach reported from81, January 8, 2014 ª2014 Elsevier Inc. 1
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Figure 1. Anti-TfR Vehicles for CNS Drug Delivery
(A) TfR-based drug delivery strategies including IgG-based molecular trojan
horse fusion proteins (left) (Pardridge, 2012), a bispecific anti-TfR/BACE1
antibody (middle) (Yu et al., 2011), and the anti-TfR sFab Brain Shuttle (right)
(Niewoehner et al., 2014).
(B) Proposed pathway for differential intracellular sorting of monovalent and
bivalent anti-TfR Fab fusions. Whereas monovalent anti-TfR sFab fusions
undergo transcytosis across the BBB, bivalent anti-TfR dFab fusions leads
to TfR dimerization and lysosomal degradation.
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this issue of Neuron.
Niewoehner et al. (2014)
began by generating brain
shuttle constructs fusing one
(sFab) or two (dFab) anti-TfR
Fab fragments to the C termi-
nus of a full-length mono-
clonal anti-Ab antibody
(mAb31) to mediate monova-
lent and bivalent binding to
TfR, respectively (Figure 1B).
Both constructs maintained
high-affinity binding to Ab
and were taken up in endo-
thelial cells via TfR endo-
cytosis. This is where the
similarities between the
two constructs diverged.
Whereas the monovalent
sFab fusion mediated effec-
tive uptake, transcytosis,
and TfR recycling, the pres-
ence of two Fab fragments on
mAb31 (dFab) resulted in up-
take followed by trafficking
to lysosomes and an associ-
ated reduction in TfR levels
(Figure 1B). The intracellular
sorting and trafficking path-
ways for recycling versus
degradation were shown
in vitro in endothelial cells
and in vivo in the PS2APP
transgenic mouse model
of Alzheimer’s disease. Nie-
woehner et al. (2014) hypo-
thesize that the presence of
two anti-TfR Fab fragments
on mAb31 results in TfR
dimerization and sorting
to lysosomes (Figure 1B). It
will be important for future
studies to define the mole-
cular basis for this differentialsorting in brain endothelium as it could
help optimize future design strategies for
transcytotic delivery.
Next, Niewoehner et al. (2014) exam-
ined the ability of the monovalent TfR
Fab-fused Ab antibody (mAb31-sFab) to
access brain parenchyma and reduce
Ab. Remarkably, mAb31-sFab exhibited
a 55-fold increase in amyloid plaque
engagement compared to unmodified
mAb31 or bivalent mAb31-dFab in the
brain of PS2APP mice. Moreover, treat-
ment with mAb31-sFab for 3 months2 Neuron 81, January 8, 2014 ª2014 Elseviersignificantly reduced amyloid plaque
burden even at a relatively low dose
when compared to treatment with un-
modified mAb31. Overall, the sFab anti-
TfR brain shuttle module enhanced the
delivery and potency of a plaque reducing
Ab antibody and could potentially be
expanded to the delivery of other
therapeutic cargo.
While this study from Niewoehner
et al. (2014) provides mechanistic insight
and hope for the delivery of macro-
molecule therapeutics across the BBB,Inc.additional studies will be
required. Fundamental ques-
tions regarding pharmacoki-
netics of TfR-based drug
delivery approaches remain.
The quantification of mAb31-
sFab brain penetration is
limited to immunofluores-
cent-based signal amplifica-
tion imaging. Detailed neuro-
pharmacokinetic analysis of
the percent injected dose in
the brain will be important.
Moreover, understanding
how affinity versus valency
influences RMT and cell
sorting will be important
for optimizing TfR drug
delivery strategies. It will
also be interesting to ex-
amine the role of extracellular
matrix, pericyte, and glial
interactions and varying dis-
ease pathology in modulat-
ing the transcytotic delivery
of macromolecules. Indeed,
in the case of Alzheimer’s
disease, Ab deposition oc-
curs within cerebrovas-
culature, which could alter
BBB function (Zlokovic,
2008). Niewoehner et al.
(2014) found that the Brain
Shuttle strategy does not
damage the BBB, but
it is important to consider
whether utilization of endo-
genous RMT pathways
interferes with physiological
processes. For example,
TfR-based transport modal-
ities have been associated
with loss of reticulocytes
(Couch et al., 2013). Under-
standing what cells andtissues will be targeted with any given
RMT-based strategy is essential when
determining toxicity risks. For instance,
delivery of GDNF with an anti-insulin
antibody in nonhuman primates led to
pancreatic lesions, presumably due
to abundance of insulin receptors and
adverse proliferative consequence of
GDNF in pancreatic cells (Ohshima-
Hosoyama et al., 2012).
Finally, the most effective RMT
pathway at the human BBB remains to
be determined. Currently, antibodies
Neuron
Previewsagainst insulin receptors do not exist
for BBB transport studies in rodents,
so anti-TfR approaches have been
the primary strategy for preclinical
testing. Whether or not this approach
will have the best translational potential
in humans has yet to be confirmed.
Variable expression of small molecule
efflux transporters such as PgP and
BCRP in different species has been
established, and it will not be surprising
if species differences exist for RMT
transport pathways. Acquisition of data
in humans or human cell models will be
required to reveal the expression and
kinetics of TfR and other RMT pathways
at the BBB.
Routine delivery of large biomolecules
across the human BBB remains a holy
grail for CNS therapeutics. More than $1
billion has been spent on clinical develop-
ment of peripherally administered Ab
antibodies that exhibit limited CNS
penetration (Yu and Watts, 2013). The
exciting finding by Freskga˚rd and col-leagues that fusion of a single anti-TfR
Fab improves brain penetration of anti-
bodies by transcytotic delivery points
toward a general strategy for CNS
delivery and may help define the basic
cell biology of membrane trafficking in
the cerebrovasculature. By identifying a
monovalent, modular means of moving
molecules into the CNS, Niewoehner
et al. (2014) provide a potentially powerful
procedure to pierce through the blood-
brain barrier.REFERENCES
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Censor et al. (2014) combine behavioral, TMS, and neuroimaging to identify task-free neural signatures that
relate to modification of motor memories. Modulation of memories using TMS may provide a powerful
approach to improve human brain function in neurorehabilitation and cognitive neuroscience.Modification of existing memories after
their reactivation may result in behavioral
outcomes that can be beneficial or
maladaptive. Numerous studies have
provided evidence that when an already
consolidated memory is reactivated
upon retrieval, it becomes susceptible to
modification before it is reconsolidated
again into a stable form (Nader and Hardt,
2009; Dudai, 2012). The outcomes of this
modification can be degradation (Nader
et al., 2000), stabilization, or strength-
ening of the original memory (Lee, 2008;Walker et al., 2003; Censor et al., 2010).
Substantial advances in the field have
been achieved using animal models, by
injecting protein synthesis inhibitors to
the relevant brain regions, upon reactiva-
tion of the memory. Progress has been
also made in humans, pointing to similar
mechanisms (Chan and LaPaglia, 2013;
Schiller et al., 2010; Schwabe et al.,
2012; Censor et al., 2010; Walker et al.,
2003). Overall, modification of existing
memories after their reactivation may
play an important role in learning and skillacquisition and, furthermore, can be of
special relevance in rehabilitation after
brain injury or in treating chronic neuro-
logical conditions. What has beenmissing
to date is evidence for task-free neural
signatures of modified human memories
at a systems level.
In this issue of Neuron, Censor et al.
(2014) start to address this question by
focusing their interest in the corticostriatal
loop, under the working hypothesis that
activity in this loop might relate to interin-
dividual differences in the ability to modify81, January 8, 2014 ª2014 Elsevier Inc. 3
